Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00005633 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL: OVA BiP peptide
BIOLOGICAL: gp209-2M antigen
BIOLOGICAL: recombinant 70-kD heat-shock protein
BIOLOGICAL: tyrosinase peptide

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]